Cerus Corporation announced its preliminary full-year 2025 product revenue of $206.1 million, reflecting a 14% increase over 2024. The company also reported fourth quarter 2025 product revenue of $57.8 million, marking a 14% year-over-year rise. Revenue from the INTERCEPT Fibrinogen Complex (IFC) showed particularly strong growth, reaching $16.7 million for the full year—an increase of approximately 80% compared to 2024. Looking ahead, Cerus expects full-year 2026 product revenue to range between $224 million and $228 million, representing anticipated growth of 9% to 11% over 2025. IFC revenue is projected to grow to $20 million to $22 million in 2026, an increase of 20% to 30% from the prior year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260111066393) on January 11, 2026, and is solely responsible for the information contained therein.